Research programme: cannabinoid based therapeutics - Cannex Scientific
Latest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator Cannex Scientific
- Class Antivirals; Anxiolytics; Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anxiety disorders; Viral infections
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for research development in Anxiety-disorders in USA
- 28 Jan 2025 No recent reports of development identified for research development in Viral-infections in USA
- 28 Jun 2021 Cannex Scientific enters into a agreement with Brigham and Women's Hospital to advance cannabinoid therapies